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Anthracyclines are effective drugs for the treatmentof malignancies. However, the use ofanthracyclines is accompanied by irreversible
dilatory cardiomyopathy in 5–20 % of cases. Drug
treatment for such cardiomyopathy is ineffective and the
condition has a mortality rate of over 50 %. Therefore,
the prevention of cardiomyopathy is clinically important.1,2
Acute intoxication appears as myocarditis and may lead to
transient hyperemia. Delayed cardiomyopathy is
characterized by fatigue, activity dyspnea, orthopenia,
bradicardia, S3 gallop, and lung edema.3,4 Cardiotoxic
symptoms may be subclinical but can be identified using
various methods of cardiac function assessment in
asymptomatic subjects. Generally, cardiac symptoms
resulting from anthracyclines may be premature and
observed during treatment or within the first year after
beginning treatment.5,6 A high cumulative dose of the
prescribed drug, radiotherapy, female gender, and young
age at the time of suffering from the background
malignancy are the most important risk factors for cardiac
complications caused by anthracycline treatment.7,8
The main mechanism of the cardiotoxic effects of
anthracyclines is not completely known but two factors are
suspected: lipid peroxidation and production of free
radicals by ferrous–anthracycline complexes.9,10
Several possible methods have been suggested to reduce the
adverse cardiac effects of anthracycline treatment, including
avoidance of anthracyclines (especially in tumors with a poor
prognosis), reduction of the prescribed cumulative dose, use
of liposome anthracyclines, immediate and early
identification of subclinical cardiac symptoms, and
use of cardioprotective agents such as dexrazoxane.2,11
Prescribing cardioprotective agents together with
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anthracyclines leads to a reduction of cardiac complications.
Apparently, dexrazoxan hinders the development and
activity of ferrous–anthracycline complexes by binding the
ferrous particles; this leads to reduced free radical production
and, thus, reduced historrhexis.12 Carvedilol obstructs β-1, 
β-2, and α-1 receptors and has strong antioxidant and
antiapoptotic effects,13 which are highly important for
cardioprotection. Also, carvedilol can suppress sarcoplasmic
reticulum Ca2- ATPase. The effects of carvedilol in
suppressing apoptosis signaling routes may play a
role in cardioprotection.14
The aim of the research presented in this article was to
study the protective effect of carvedilol in cardiomyopathy
caused by anthracyclines in patients suffering from breast
cancer and lymphoma.
Methods 
Over the course of one year, patients with a diagnosis of
breast malignancies and lymphoma who were under
treatment with anthracyclines and who were referred to
Shahid Ghazi Clinic entered the study and were followed
up for four months. The following patients were excluded
from the study: patients with records of chemotherapy,
radiotherapy, symptoms of hyperemia, and cardiac
insufficiency; patients with approved restrictive and
hyperemia cardiomyopathy; patients with coronary vessel
disease; those with moderate to severe insufficiency of the
mitral and aortic valves in early echocardiography;
patients with ramous blocks; patients with thyroid
dysfunction; patients in whom carvedilol was
contraindicated; patients with serious concurrent disease;
patients taking angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, diuretics, or beta-blockers;
and patients under 12 years of age. 
In this clinical trial, 66 patients undergoing chemotherapy
were randomly divided into three groups, each containing
22 patients. The first group received placebo and the second
and third groups received, respectively, 12.5 mg and 25 mg
of apo-carvedilol 24 hours before starting the study. The
study lasted for four months. Doxorubicin and epirubicin
were prescribed at 50–60 mg and 100 mg per square meter of
body area, respectively. The patients in this study underwent
echocardiography and tissue Doppler using Vingmed
System 7 to look for cardiomyopathy. Left ventricular
function was measured during systole and diastole before
starting chemotherapy and during the acute phase (in cases
where clinical symptoms of cardiomyopathy appeared) and
during the chronic phase in the fourth month. Anolous
movement of the mitral valve was used to calculate 
the ejection fraction. A questionnaire was used to collect the
required information: age, gender, mortality, type of
malignancy, type of chemotherapy regimen and cycle,
cumulative dose of doxorubicin and epirubicin,
echocardiography results (left ventricular ejection fraction,
diastolic end diameter of the left ventricle, systolic 
end diameter of the left ventricle, E-wave velocity, E/A ratio),
results of tissue Doppler (including maximum systolic
velocity of the mitral valve, Ei/Ea ratio, inferior–posterior
movement of the mitral valve, speed development), and
pure systolic and diastolic cardiomyopathy. 
The obtained data were analyzed using SPSSTM-15
statistical software. Quantitative variables were compared
using the Student t-test (independent samples, paired
samples t-test). Categorical variables were compared using
contingency tables and the chi-squared test or Fisher’s
exact test. In all cases, the results were seen as statistically
significant if p≤0.05.
Results
No significant differences were observed among the groups
in terms of mortality, age, gender, type of malignancy,
chemotherapy regimen, and cumulative dose of doxorubicin
and epirubicin (see Table 1). The average cumulative dose of
doxorubicin was 540.28±31.17 mg/m2 in the control group,
531.50±29.98 mg/m2 in the group receiving 12.5 mg
carvedilol, and 521.14±38.97 mg/m2 in the group receiving
25 mg carvedilol; taking the two groups receiving carvedilol
together (case group), the average cumulative dose of
doxorubicin was 540.28±31.17 mg/m2. In this regard, no
statistically significant difference was observed between the
control and case groups (p=0.218). The average cumulative
dose of epirubicin was 768.44±26.78 mg/m2 in the control
Table 1: Patients’ Demographic Information 
                         Placebo           12.5 mg           25 mg              Carvedilol 
                                                 Carvedilol        Carvedilol        (both groups)
GENDER (P=0.569)
Male                 8                     7                      5                       5
Female              14                   15                    17                    17
AGE (YEARS) (P=0.098)
                        43.50±15.27   45.70±14.16    52.52±11.00    43.50±15.27
TYPE OF MALIGNANCY (P=0.140)
Lymphoma      9                     5                      5                       6
Breast               13                   17                    17                    16
CHEMOTHERAPY REGIMEN
CHOP               6                     3                      2                       4
ABVD               2                     1                      2                       2
CAF                  10                   16                    17                    15
MORTALITY (P=0.210)
                        4                     2                      1                       1
ABVD = adriamycin, bleomycin, vinblastine, dacarbazine; 
CAF = cyclophosphamide, doxorubicin, fluorouracil; CHOP = cytoxan,
hydroxyrubicin (Adriamycin), oncovin (Vincristine), prednisone.
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group, 764.25±31.21 mg/m2 in the group receiving 12.5 mg
carvedilol, 770.90±25.17 mg/m2 in the group receiving
25 mg carvedilol, and 768.44±26.87 mg/m2 in the case
group. In this regard, no statistically significant difference
was observed between the control and case groups (p=0.744).
Five patients in the control group, five patients in the group
receiving 12.5 mg carvedilol, and one patient
in the group receiving 25 mg carvedilol (a total of six
patients in the case group) developed systolic
cardiomyopathy. In this regard, no statistically significant
difference was observed between the control and case
groups (p=0.284). Also, there was no statistically significant
difference in the frequency of systolic cardiomyopathy
between the control group and the group receiving 12.5 mg
carvedilol (p=1), between the control group and the group
receiving 25 mg carvedilol (p=0.077),and between the two
groups receiving carvedilol (p=0.093).
Five patients in the control group, three patients in the
group receiving 12.5 mg carvedilol, and three patients 
in the group receiving 25 mg carvedilol (a total of six
patients in the case group) developed pure diastolic
cardiomyopathy. In this regard, no statistically significant
difference was observed between the control and case groups
(p=0.284). Also, there was no statistically significant
difference in the frequency of diastolic cardiomyopathy
between the control group and the group receiving 12.5 mg
carvedilol (p=0.438), between the control group and the
group receiving 25 mg carvedilol (p=0.432), and between 
the two groups receiving carvedilol (p=1) (see Table 2).
Discussion
This study considered the effects of carvedilol in
preventing cardiomyopathy resulting from anthracycline
treatment in patients suffering from breast cancer and
lymphoma. Carvedilol was prescribed at either 12.5 mg or
25 mg per day for four months. At the end of the study,
although the frequency of pure systolic and diastolic
cardiomyopathy was lower in the group receiving
carvedilol than in the control group (27.8 % versus
14.6 %), the difference was not statistically significant. On
the other hand, studies using 2D echocardiography and
color Doppler have demonstrated that carvedilol at a daily
dose of 12.5 mg has a protective effect against diastolic
disorders and at a daily dose of 25 mg had a protective
effect against both systolic and diastolic disorders. 
In 2002, Santos et al. demonstrated that prophylactic
prescription of carvedilol may prevent mitochondrial
cardiomyopathy caused by doxorubicin.15 In 2007, Cruz et
al., using a hamster model, suggested that carvedilol at a
daily dose of 1 mg/kg body weight may lead to improved
cardiac function.16 Thus, these two studies confirm the
protective effect of carvedilol in animal models. In a study
in Turkey in 2006, Kalay et al. randomized 50 patients
suffering from breast cancer or lymphoma to receive
placebo or carvedilol. This study showed that carvedilol (at
the mentioned dose) had a protective effect on systolic and
diastolic disorders of the left ventricle resulting from
anthracycline treatment.17 As discussed above, our study
observed a protective effect on both systolic and diastolic
disorders with the 25 mg dose of carvedilol daily, while the
12.5 mg daily dose maintained diastolic (but not systolic)
function of the left ventricle. 
There are two main limitations in the study by Kalay et al.,
including the low-density sample and failure to study the
long-term effects of anthracycline in cardiac cases.
According to the results of this study, a daily dose of 25 mg
of carvedilol may play a protective role in preventing
systolic and diastolic disorders of the left ventricle,
although there was no statistically significant difference in
the frequency of clinical cardiomyopathy between the
groups studied. Kalay et al. reported mortality rates 
in the control and case groups of 16 % and 4 %,
respectively. The result was not statistically significant;
however, the study concluded that, although the
Table 2: Inter- and Intra-group Comparison of Echocardiography
and Tissue Doppler Variables  
                            Placebo            12.5 mg          25 mg            Carvedilol 
                                                         Carvedilol        Carvedilol       (Both Groups)
LEFT VENTRICULAR MUTATION FRACTION (P=0.375)
Baseline              58.56±3.62      60.5±5.07       61.00±7.06    58.56±3.62
4 months later    53.94±3.80      53.15±7.76     56.81±6.20    53.94±3.80
DIASTOLIC END DIAMETER OF LEFT VENTRICLE (MM) (P=0.226)
Baseline              4.13±0.61        4.17±0.39       3.93±0.34      4.13±0.61
4 months later    4.56±0.57        4.50±0.46       4.09±0.37      4.56±0.57
SYSTOLIC END DIAMETER OF LEFT VENTRICLE (MM) (P=0.069)
Baseline              3.00±0.35        2.92±0.44       2.73±0.29      3.01±0.35
4 months later    3.24±0.44        3.00±0.55       2.85±0.35      3.24±0.44
E WAVE VELOCITY (CM/S) (P=0.086)         
Baseline              68.5±14.67      75.5±13.71     67.38±5.04    67.38±5.04
4 months later    63.1±10.71      71.35±12.68   66.43±5.03    63.06±10.71
E/A RATIO (P=0.087)
Baseline              0.99±0.45       7.03±0.21       0.83±0.17      0.99±0.45
4 months later    0.86±0.33        1.00±0.38       0.81±0.17      0.86±0.33
MAXIMUM SYSTOLIC VELOCITY OF MITRAL VALVE (P=0.939)
Baseline              17.56±2.38      17.25±2.77     17.33±2.92    17.56±2.38
4 months later    16.61±1.50      17.05±3.24     15.38±4.34    16.61±1.50
EI/EA RATIO (P=0.518)
Baseline              3.53±1.02        3.37±0.97       3.69±0.66      3.53±1.02
4 months later    3.88±0.78        3.51±0.80       3.79±0.66      3.88±0.78
INTERIOR–POSTERIOR MOVEMENT OF MITRAL VALVE (MM) (P=0.061)
Baseline              16.94±3.11      17.00±2.36     18.81±2.29    16.94±3.11
4 months later    15.44±1.89      16.36±1.42     18.67±2.44    15.44±1.86
SPEED DEVELOPMENT (CM/S) (P=0.053)
Baseline              58.72±8.17      65.90±10.78   66.38±12.09  58.72±8.17
4 months later    52.17±8.83     62.95±9.58     64.90±9.80    52.17±8.83
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difference is not statistically significant owing to the 
low-density sample, it is considerable.17
In 2004, Mukai et al. verified the effects of carvedilol at an
initial dose of 2 mg per day increasing to 10–20 mg per 
day in five patients suffering from cardiomyopathy caused
by anthracyclines. The study showed that carvedilol was
successful in improving patients’ symptoms and
maintaining ventricular function and diastolic and systolic
diameters.12 This finding contradicts the results of studies
showing that cardiomyopathy caused by anthracyclines is
irreversible.18 Therefore, it is necessary to study the role of
carvedilol in treating clinical cases, considering its possible
effect in treating and preventing cardiomyopathy resulting
from chemotherapy.
It should be noted that the suggested dose of carvedilol in
patients with heart failure is 12.5–50 mg, according to 
the MOCHA study.19 There is no general agreement 
on the appropriate dose of carvedilol in cardiovascular
patients because the protective effect of the drug on
cardiomyopathy caused by chemotherapy has not yet
been comprehensively studied and further studies 
are required.20
It should also be noted that a daily dose of 12.5 mg
carvedilol may lead to decrease of echocardiography and
tissue Doppler in favor of diastolic disorders, and a daily
dose of 25 mg carvedilol may lead to decrease of
echocardiography and tissue Doppler in favor of diastolic
and diastolic disorders. n
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